Atrial Fibrillation, Natural Treatment in Denver Area
NatureMed clinic is located in southeast Boulder. We are 20 minutes from Central Denver. We serve patienrs in the greater Denver area. Dr. Steve Parcell heads the integrative cardiology group there. NatureMed integrates conventional, Western, allopathic medicine with holistic, naturopathic medicine using science based approaches that work.
Atrial fibrillation is the most common arrhythmia worldwide and is a significant risk factor for stroke and peripheral embolism (blood clot). It has negative effects on cardiac function. It typically starts after age 50 and is more common as people get older. It is more common in Caucasians than other races. Often it is fixable with naturopathic approaches. We monitor patients with ECG often using a holter monitor.
There are 3 main types of atrial fibrillation
· Paroxysmal atrial fibrillation: Spontaneously starts and stops only lasts for a day or 2
· Persistent atrial fibrillation last longer than a week with symptoms are stopped following cardio conversion
· Long-standing persistent atrial fibrillation last longer than a year and the patient usually takes a rhythm control medication
Symptoms of atrial fibrillation
· Shortness of breath
· Chest pain or discomfort
Conditions associated with increased chance of getting atrial fibrillation
· High blood pressure
· Coronary artery disease
· Sleep apnea
· Heart valve problems
· Alcohol abuse
The goal of treatment
· Prevent clots
· Control heart rate
· Restore and maintain regular rhythm as much as possible
Conventional treatment involves medication such as beta blockers and calcium channel blockers as well as anticoagulants such as Coumadin and Pradaxa. Electrical cardioversion helps restore normal heart rhythm and medication does not improve symptoms but does not always fix the problem. Patients often complain of side effects from the medications. Patients over the age of 70 with no coexisting disease may be candidates for ablation therapy. Occasionally very ill patients who are also older are sometimes candidates for ablation because the stroke risk is so high and they cannot tolerate the medications. The success rate of ablation worldwide is about 70% in patients who follow up with their doctor.
Antiarrhythmic medication side effects
· slow heartbeat
· stomach pain
· skin rash
· vision problems
· urinary retention in men
Naturopathic perspective and considerations
Many patients are tired of “rat poison” (Coumadin) and medications that cause too many side effects such as fatigue and dizziness. Naturopathic treatment is individualized to the patient and may include:
· Losing weight
· Limiting alcohol
· Limiting caffeine
· Addressing magnesium deficiency with intravenous magnesium
· Controlling stress
· Preventing vitamin K deficiency in patients on Coumadin
· Evaluating stroke risk with special blood tests not typically ordered by insurance based doctors
· Use plant medicines such as Hawthorne extract
· Use natural anticoagulants such as nattokinase and lumbrokinase
· Follow up with blood tests to ensure efficacy of blood thinning effect
Intravenous magnesium can be highly effective!
Magnesium regulates cellular enzymatic and metabolic processes throughout the body. In myocardial (heart muscle) cells, magnesium antagonizes (acts against) calcium and potassium channels. Magnesium has been shown to affect the transport of ions that regulate the cardiac muscle action potential. In addition, electrophysiologic studies have demonstrated slowed cardiac conduction and increased cardiac refractoriness with administration of magnesium. Magnesium has an accepted role in the management of ventricular arrhythmias, including torsade de pointes. Electrolyte imbalances may contribute to the development of atrial tachyarrhythmias (irregular fast heart beat) by causing abnormal impulse generation, which could initiate atrial fibrillation.
Electrophysiologic studies performed in humans with normal serum magnesium concentrations have demonstrated that time required to conduct an impulse through the atrial tissue and time of unresponsiveness to electrical stimuli are increased after administration of intravenous magnesium. This means that the heart muscle (myocardium) can become less sensitive to stimuli, including nervous system input.
Serum magnesium concentrations are often used to monitor magnesium status and to guide supplementation therapy. Unfortunately, magnesium measured in the serum represents only about 1% of the total body content of the electrolyte. Blood magnesium levels are NOT ACCURATE in assessing intracellular magnesium stores.
We like to analyze epithelial cells collected from a patient's oral mucosa. Measurement of intracellular magnesium levels in cells swabbed from the patient's mouth with use of a noninvasive test correlates well with intracellular magnesium levels obtained from atrial tissue samples of patients undergoing cardiac surgery.
· Serum magnesium concentration is an imperfect measure of total-body magnesium content. Noninvasive measurement of intracellular magnesium concentrations provide added insight into the true role of total-body magnesium content in the etiology of atrial tachyarrhythmias.
· Intravenous magnesium is very effective in managing atrial fibrillation.
· The amino acids, in addition to some botanical medicines can also be effective.
· Diet and lifestyle modifications also help.
· Some patients may not respond to naturopathic treatment and may need ablation. In our experience 80% of patients with atrial fibrillation get definitive improvement with our integrative, naturopathic approach at our Boulder office that treats the cause of A Fib.
1. American Heart Association. Heart disease and stroke statistics -- 2003 update. Dallas: American Heart Association, 2002.
2. Rubart M, Zipes DP. Genesis of cardiac arrhythmias: electrophysiolical considerations. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular medicine, 6th ed. Philadelphia: WB Saunders Co., 2001:659-99.
3. Kass RS, Blair ML. Effects of angiotensin II on membrane current in cardiac Purkinje fibers. J Mol Cell Cardiol 1981;13:797-809.
4. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-7.
5. Reinhart RA. Clinical correlates of the molecular and cellular actions of magnesium on the cardiovascular system. Am Heart J 1991;121:1513-21.
6. White RE, Hartzell HC. Magnesium ions in cardiac function: regulator of ion channels and second messengers. Biochem Pharmacol 1989;38:859-67.
7. Rasmussen HS, Thomsen PEB. The electrophysiologic effects of intravenous magnesium on human sinus node, atrioventricular node, atrium, and ventricle. Clin Cardiol 1989;12:85-90.
8. DiCarlo LA, Morady FM, DeBuitleir M, Krol RB, Schurig L, Annesley TM. Effects of magnesium sulfate on cardiac conduction and refractoriness in humans. J Am Coll Cardiol 1986;7:1356-62.
9. Keller PK, Aronson RS. The role of magnesium in cardiac arrhythmias. Prog Cardiovasc Dis 1990;32:433-48.
10. American Heart Association and the International Liaison Committee on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiac care. Circulation 2000;102(suppl 8):I1-370.
11. Miller B, Craddock L, Hoffenberg S, et al. Pilot study of intravenous magnesium sulfate in refractory cardiac arrest: safety data and recommendations for future studies. Resuscitation 1995;30:3-14.
12. Thel MC, Armstrong AL, McNulty SE, Califf RM, O'Connor CM, for the Duke Internal Medicine Housestaff. Randomised trial of magnesium in in-hospital cardiac arrest. Lancet 1997;350:1272-6.
13. The Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the magnesium in coronaries (MAGIC) trial: a randomized controlled trial. Lancet 2002;360:1189-96.
14. Bauman JL, Schoen MD. Arrhythmias. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. New York: McGraw-Hill, 2002:273-303.
15. DeCarli C, Sprouse G, LaRosa JC. Serum magnesium levels in symptomatic atrial fibrillation and their relation to rhythm control by intravenous digoxin. Am J Cardiol 1986;57:956-9.
16. Reinhart RA, Marx JJ, Broste SK, Haas RG. Myocardial magnesium: relation to laboratory and clinical variables in patients undergoing cardiac surgery. J Am Coll Cardiol 1991;17:651-6.
17. Haigney MCP, Silver B, Tanglao E, et al. Noninvasive measurement of tissue magnesium and correlation with cardiac levels. Circulation 1995;92:2190-7.
18. Haigney MCP, Berger R, Schulman S, et al. Tissue magnesium levels and the arrhythmic substrate in humans. J Cardiovasc Electrophysiol 1997;8:980-6.
19. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001;43(suppl 1):1-45.
20. Surawicz B. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarization? J Am Coll Cardiol 1989;14:172-84.
21. Dilaveris PE, Gialafos EJ, Sideris SK, et al. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 1998;135:733-8.
22. Greineder K, Strichartz GR, Lilly LS. Basic cardiac structure and function. In: Lilly LS, ed. Pathophysiology of heart disease, 2nd ed. Baltimore: Williams and Wilkins, 1998:1-23.
23. Roden DM. Antiarrhythmic drugs. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996:839-74.
24. Wu JY, Lipsius SL. Effects of extracellular Mg++ on T- and L-type Ca++ currents in single atrial myocytes. Am J Physiol 1990;259(6 pt 2):H1842-50.
25. Duchatelle-Gourdon I, Hartzell HC, Lagrutta AA. Modulation of the delayed rectifier potassium current in frog cardiomyocytes by b-adrenergic agonists and magnesium. J Physiol 1989;415:251-74.
26. White CM, Xie J, Chow MSS, Kluger J. Prophylactic magnesium to decrease the arrhythmogenic potential of class III antiarrhythmic agents in a rabbit model. Pharmacotherapy 1999;19:635-40.
27. Davidenko JM, Cohen L, Goodrow R, Antzelevitch C. Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers: effects of stimulation rate, potassium and magnesium. Circulation 1989;79:674-86.
28. Verduyn SC, Vos MA, van der Zande J, van der Hulst FF, Wellens HJ. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium. Cardiovasc Res 1997;34:453-63.
29. Fuster V, Ryde´n LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and electrophysiology. J Am Coll Cardiol 2001;38:1231-66.
30. Chen YJ, Chen SA, Chang MS, Lin CI. Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation. Cardiovasc Res 2000;48:265-73.
31. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995;92:1954-68.
32. Hays JV, Gilman JK, Rubal BJ. Effect of magnesium sulfate on ventricular rate control in atrial fibrillation. Ann Emerg Med 1994;24:61-4.
33. Frick M, Ostergren J, Rosenqvist M. Effect of intravenous magnesium on heart rate and heart rate variability in patients with chronic atrial fibrillation. Am J Cardiol 1999;84:104-8.
34. Brodsky MA, Orlov MV, Capparelli EV, et al. Magnesium therapy in new-onset atrial fibrillation. Am J Cardiol 1994;73:1227-9.
35. Moran JL, Gallagher J, Peake SL, Cunningham DN, Salagaras M, Leppard P. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Crit Care Med 1995;23:1816-24.
36. Gullestad L, Birkeland K, Molstad P, Hoyer MM, Vanberg P, Kjekshus J. The effect of magnesium versus verapamil on supraventricular arrhythmias. Clin Cardiol 1993;16:429-34.
37. Chiladakis JA, Stathopoulos C, Davlouros P, Manolis AS. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int J Cardiol 2001;79:287-91.
38. Kalus JS, Spencer AP, Tsikouris JP, et al. Impact of prophylactic i.v. magnesium on the efficacy of ibutilide for conversion of atrial fibrillation or flutter. Am J Health-Syst Pharm 2003;60:2308-12.
39. Caron MF, Kluger J, Tsikouris JP, Ritvo A, Kalus JS, White CM. Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide. Pharmacotherapy 2003;23:296-300.
40. Falk RH, Knowlton AA, Vernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med 1987;106:503-6.
41. Daoud EG, Knight BP, Weiss R, et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997;96:1542-50.
42. Kurita Y, Mitamura H, Shiroshita-Takeshita A, et al. Daily oral verapamil before but not after rapid atrial excitation prevents electrical remodeling. Cardiovasc Res 2002;54:447-55.
43. Frick M, Darpo B, Ostergren J, Rosenqvist M. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. Eur Heart J 2000;21:1177-85.
44. Pinson JB, Weart CW. Acid-peptic products. In: Covington TR, ed. Handbook of nonprescription drugs. Washington, DC: American Pharmaceutical Association, 1996:193-224.
45. Niche Pharmaceuticals Inc. Mag-Tab SR (magnesium L-lactate dihydrate) product information. Roanoke, TX. Available from http://www.niche-inc.com/niche/magtab.html. Accessed August 14, 2003.
46. Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002;106:75-80.
47. England MR, Gordon G, Salem M, et al. Magnesium administration and dysrhythmias after cardiac surgery. JAMA 1992;268:2395-402.
48. Parra L, Fita G, Gomar C, et al. Plasma magnesium in patients submitted to cardiac surgery and its influence on perioperative morbidity. J Cardiovasc Surg 2001;42:37-42.
49. Vyvyan HAL, Mayne PN, Cutfield GR. Magnesium flux and cardiac surgery: a study of the relationship between magnesium exchange, serum magnesium levels and postoperative arrhythmias. Anaesthesia 1994;49:245-9.
50. Bert AA, Reinert SE, Singh AK. A β-Blocker, not magnesium, is effective prophylaxis for atrial tachyarrhythmias after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2001;15:204-9.
51. Solomon AJ, Berger AK, Trivedi KK, Hannan RL, Katz NM. The combination of propranolol and magnesium does not prevent postoperative atrial fibrillation. Ann Thorac Surg 2000;69:126-9.
52. Parikka H, Toivonen L, Pellinen T, Verkkala K, Jarvinen A, Nieminen MS. The influence of intravenous magnesium sulphate on the occurrence of atrial fibrillation after coronary artery by-pass operation. Eur Heart J 1993;14:251-8.
53. Toraman F, Karabulut H, Alhan C, Dagdelen S, Tarcan S. Magnesium infusion dramatically decreases the incidence of atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2001;72:1256-62.
54. Fanning WJ, Thomas CS, Roach A, Tomichek R, Alford WC, Stoney WS. Prophylaxis of atrial fibrillation with magnesium sulfate after coronary artery bypass grafting. Ann Thorac Surg 1992;52:529-33.
55. Forlani S, De Paulis R, de Notaris S, et al. Combination of sotalol and magnesium prevents atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2002;74:720-6.
56. Wistbacka JM, Koistinen J, Kalqvist KEV, et al. Magnesium substitution in elective coronary artery surgery: a double-blind clinical study. J Cardiothorac Vasc Anesth 1995;9:140-6.
57. Casthely PA, Yoganathan T, Komer C, Kelly M. Magnesium and arrhythmias after coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1994;8:188-91.
58. Colquhoun IW, Berg GA, el-Fiky M, Hurle A, Fell GS, Wheatley DJ. Arrhythmia prophylaxis after coronary artery surgery: a randomized controlled trial of intravenous magnesium chloride. Eur J Cardiothorac Surg 1993;7:520-3.
59. Eray O, Akca S, Pekdemir M, Eray E, Cete Y, Oktay C. Magnesium efficacy in magnesium deficient and nondeficient patients with rapid ventricular response atrial fibrillation. Eur J Emerg Med 2000;7:287-90.
60. Speziale G, Ruvolo G, Fattouch K, et al. Arrhythmia prophylaxis after coronary artery bypass grafting: regimens of magnesium sulfate administration. Thorac Cardiovasc Surg 2000;48:22-6.
61. Kaplan M, Kut MS, Icer UA, Demirtas MM. Intravenous magnesium sulfate prophylaxis for atrial fibrillation after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:344-52.
62. Ali IM, Sanalla AA, Clark V. β-Blocker effects on postoperative atrial fibrillation. Eur J Cardiothorac Surg 1997;11:1154-7.
63. Tsikouris JP, Kluger J, Song J, White CM. Changes in P-wave dispersion and P-wave duration following open heart surgery are associated with the peak incidence of atrial fibrillation. Heart Lung 2001;30:466-71.
64. Intracellular Diagnostics Inc. Magnesium and heart disease. Available from http://www.exatest.com/. Accessed October 17, 2003.